| Previous close | 0.0741 |
| Open | 0.0740 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0730 - 0.0980 |
| 52-week range | 0.0680 - 1.2500 |
| Volume | |
| Avg. volume | 37,561 |
| Market cap | 3.043M |
| Beta (5Y monthly) | -0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3900 |
| Earnings date | 12 Jul 2024 - 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.50 |
GlobeNewswireMaxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET
NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Maxim Group LLC, a full-service investment banking, securities and wealth management firm, and M-Vest, a digital community built for issuers, investors, and thought leaders, present the 2024 Healthcare IT Virtual Conference. The conference will take place on Wednesday, January 24th, & Thursday, January 25th, 2024, starting at 9:00 a.m. ET. We will be presenting our 2024 Healthcare IT Virtual Conference. Allen Klee, Senior Research Analyst at Maxim Grou
GlobeNewswireImportant Update on Listing Status and Strategic Direction
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. Background: After thorough analysis, Nemaura Medical’s Board of Directors and management team have made the strategic decision t
- GlobeNewswire
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing
